Ultragenyx Pharmaceutical (RARE) Cost of Revenue (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Cost of Revenue data on file, last reported at $30.0 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $30.0 million, up 3.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.3 million (up 24.72% YoY), and the FY2025 annual result was $109.0 million, up 41.56% from the prior year.
• Cost of Revenue rose to $30.0 million in Q1 2026 per RARE's latest filing, from $29.3 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $30.0 million in Q1 2026 and troughed at $5.3 million in Q4 2022.
• A 5-year average of $17.0 million and a median of $17.2 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2026: Cost of Revenue soared 163.71% in 2022, then advanced 3.45% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $5.3 million in 2022, then soared by 122.64% to $11.8 million in 2023, then surged by 44.96% to $17.2 million in 2024, then surged by 70.95% to $29.3 million in 2025, then grew by 2.23% to $30.0 million in 2026.
• Business Quant data shows RARE's Cost of Revenue at $30.0 million in Q1 2026, $29.3 million in Q4 2025, and $28.0 million in Q3 2025.